George Nomikos - 01 Nov 2022 Form 4 Insider Report for Lipocine Inc. (LPCN)

Reporting relationship: Chief Medical Officer
Issuer ticker: LPCN
Reported as of: 01 Nov 2022
Net transaction value: +$50,750
SEC form: 4
Accepted by SEC: 08 Nov 2022, 10:57:25 UTC
Source filing: View source filing
Reporting owner signature: /s/ George Nomikos

Key filing fact

George Nomikos filed Form 4 for Lipocine Inc. (LPCN) on 08 Nov 2022.

Key facts

This page summarizes George Nomikos's Form 4 filing for Lipocine Inc. (LPCN).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 08 Nov 2022, 10:57.

Change

No earlier filing in this sequence is available for direct comparison.
Current net transaction value: +$50,750.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

LPCN transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value: $50,750
Shares: +125,000
Change %
Price: $0.4060
Shares after: 125,000
Date: 01 Nov 2022
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 125,000
Exercise price: $0.4060
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

Subject to vesting whereby 1/3 of the shares subject to the award will vest on the one year anniversary of November 1, 2023, while the remaining 2/3 of the shares subject to the award will vest monthly on a prorated basis over the following two years.